EA200970279A1 - Ингибиторы киназ, полезные для лечения пролиферативных заболеваний - Google Patents
Ингибиторы киназ, полезные для лечения пролиферативных заболеванийInfo
- Publication number
- EA200970279A1 EA200970279A1 EA200970279A EA200970279A EA200970279A1 EA 200970279 A1 EA200970279 A1 EA 200970279A1 EA 200970279 A EA200970279 A EA 200970279A EA 200970279 A EA200970279 A EA 200970279A EA 200970279 A1 EA200970279 A1 EA 200970279A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- treatment
- cancer
- present
- diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 108091000080 Phosphotransferase Proteins 0.000 abstract 3
- 102000020233 phosphotransferase Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000009929 raf Kinases Human genes 0.000 abstract 2
- 108010077182 raf Kinases Proteins 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010027406 Mesothelioma Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Настоящее изобретение относится к новым ингибиторам киназ и соединениям, модулирующим киназы, которые можно применять для лечения различных заболеваний. В частности, изобретение относится к таким соединениям, аддуктам киназа/соединение, способам лечения заболеваний и способам синтеза соединений. Соединения можно применять преимущественно для модуляции киназной активности Raf-киназ и различных полиморфных форм Raf-киназ, встречающихся при заболеваниях. Соединения согласно настоящему изобретению находят применение в лечении различных видов рака млекопитающих и, в частности, человека, включая, но не ограничиваясь, злокачественную меланому, рак кишечника, рак яичника, сосочковую карциному щитовидной железы, немелкоклеточный рак легкого и мезотелиому. Соединения согласно настоящему изобретению также находят применение при лечении ревматоидного артрита и ретинопатий, включая диабетическую нейропатию сетчатки и дегенерацию желтого пятна.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84455206P | 2006-09-14 | 2006-09-14 | |
US11/854,293 US7897762B2 (en) | 2006-09-14 | 2007-09-12 | Kinase inhibitors useful for the treatment of proliferative diseases |
PCT/US2007/078394 WO2008033999A2 (en) | 2006-09-14 | 2007-09-13 | Kinase inhibitors useful for the treatment of proliferative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200970279A1 true EA200970279A1 (ru) | 2009-10-30 |
Family
ID=39184590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970279A EA200970279A1 (ru) | 2006-09-14 | 2007-09-13 | Ингибиторы киназ, полезные для лечения пролиферативных заболеваний |
Country Status (10)
Country | Link |
---|---|
US (2) | US7897762B2 (ru) |
EP (1) | EP2063896A4 (ru) |
JP (1) | JP2010503701A (ru) |
KR (2) | KR20110074633A (ru) |
AU (1) | AU2007296441A1 (ru) |
BR (1) | BRPI0716844A2 (ru) |
CA (1) | CA2664009A1 (ru) |
EA (1) | EA200970279A1 (ru) |
MX (1) | MX2009002813A (ru) |
WO (1) | WO2008033999A2 (ru) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
MX2010009207A (es) * | 2008-02-22 | 2011-03-03 | Irm Llc | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. |
JP2011513332A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのraf阻害剤としてのn−(6−アミノピリジン−3−イル)−3−(スルホンアミド)ベンズアミド誘導体 |
TW200940539A (en) * | 2008-02-29 | 2009-10-01 | Array Biopharma Inc | RAF inhibitor compounds and methods of use thereof |
WO2009111277A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
KR20100122505A (ko) * | 2008-02-29 | 2010-11-22 | 어레이 바이오파마 인크. | Raf 저해물질 화합물 및 이들의 이용 방법 |
CN101875627B (zh) * | 2009-04-30 | 2014-01-15 | 凯惠科技发展(上海)有限公司 | 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体 |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
BR112013021896A2 (pt) * | 2011-02-28 | 2016-11-08 | Array Biopharma Inc | inibidores de serina/treonina cinase |
CN103476943A (zh) | 2011-03-10 | 2013-12-25 | 普罗维克图斯药品公司 | 用于增强治疗癌症的局部和全身性免疫调节疗法的组合 |
US8680066B2 (en) * | 2011-04-05 | 2014-03-25 | The United States of America as represented by the Development of Veterans Affairs | Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject |
RU2606131C2 (ru) | 2011-05-13 | 2017-01-10 | Эррэй Биофарма Инк. | СОЕДИНЕНИЯ ПИРРОЛИДИНИЛМОЧЕВИНЫ И ПИРРОЛИДИНИЛТИОМОЧЕВИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ TrkA |
CN102816162B (zh) * | 2011-06-10 | 2016-04-27 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
CN103974953B (zh) | 2011-12-09 | 2016-06-29 | 奇斯药制品公司 | 激酶抑制剂 |
AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
SG10201610416TA (en) | 2012-06-13 | 2017-01-27 | Incyte Corp | Substituted tricyclic compounds as fgfr inhibitors |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
AU2013344886B2 (en) | 2012-11-13 | 2017-06-29 | Array Biopharma Inc. | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain |
US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9546156B2 (en) | 2012-11-13 | 2017-01-17 | Array Biopharma Inc. | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078408A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
NZ708028A (en) | 2012-11-13 | 2018-12-21 | Array Biopharma Inc | N-pyrrolidinyl, n’-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
SI2986610T1 (en) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Bicyclic heterocycles as inhibitors of FGFR |
HUE045340T2 (hu) | 2014-05-15 | 2019-12-30 | Array Biopharma Inc | 1-((3S,4R)-4-(3-fluorfenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2- metilpirimidin-5-il)-1-fenil-1H-pirazol-5-il)karbamid mint TrkA kináz inhibitor |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MX2020004108A (es) | 2015-02-20 | 2022-01-03 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr). |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
EP3394058B1 (en) | 2015-12-23 | 2020-10-14 | Chiesi Farmaceutici S.p.A. | N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors |
KR101897631B1 (ko) * | 2016-08-10 | 2018-09-12 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 3,4-다이하이드로피리미도[4,5-d]피리미딘-2(1H)-온 골격의 유레아 화합물 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CA3089566A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
AR115296A1 (es) * | 2018-12-27 | 2020-12-16 | Agios Pharmaceuticals Inc | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer |
AU2019416117B2 (en) | 2018-12-28 | 2024-05-02 | Deciphera Pharmaceuticals, Llc | CSF1R inhibitors for use in treating cancer |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
PE20220597A1 (es) | 2019-05-10 | 2022-04-22 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos |
TW202108574A (zh) | 2019-05-10 | 2021-03-01 | 美商迪賽孚爾製藥有限公司 | 雜芳基胺基嘧啶醯胺自噬抑制劑及其使用方法 |
WO2020257180A1 (en) | 2019-06-17 | 2020-12-24 | Deciphera Pharmaceuticals, Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
JP2022544234A (ja) | 2019-08-12 | 2022-10-17 | デシフェラ・ファーマシューティカルズ,エルエルシー | 胃腸間質腫瘍を治療するためのリプレチニブ |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR20220123058A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물 |
EP4084778B1 (en) | 2019-12-30 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Amorphous kinase inhibitor formulations and methods of use thereof |
KR102382613B1 (ko) * | 2020-01-15 | 2022-04-06 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물 |
MX2023003995A (es) | 2020-10-05 | 2023-06-12 | Enliven Inc | Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl. |
KR20230121758A (ko) | 2020-11-18 | 2023-08-21 | 데시페라 파마슈티칼스, 엘엘씨. | Gcn2 및 perk 키나제 억제제 및 그의 사용 방법 |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ505845A (en) | 1997-12-22 | 2003-10-31 | Bayer Ag | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
ES2154253T3 (es) | 1997-12-22 | 2012-01-27 | Bayer Healthcare Llc | Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas. |
NZ510760A (en) | 1998-10-23 | 2003-08-29 | F | Bicyclic nitrogen heterocycles |
KR20020063854A (ko) * | 1999-09-17 | 2002-08-05 | 애보트 게엠베하 운트 콤파니 카게 | 치료제로서의 키나제 억제제 |
US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
US20040023961A1 (en) | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
US7196090B2 (en) | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
US7112676B2 (en) | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
AR043059A1 (es) * | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
US20040171075A1 (en) | 2002-12-31 | 2004-09-02 | Flynn Daniel L | Modulation of protein functionalities |
US20060004011A1 (en) | 2003-06-30 | 2006-01-05 | Bayer Pharmaceuticals Corporation | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
CA2533774A1 (en) | 2003-07-29 | 2005-02-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
JP2008525502A (ja) | 2004-12-23 | 2008-07-17 | デシファラ ファーマスーティカルズ, エルエルシー | 抗炎症薬 |
AU2005321946B2 (en) | 2004-12-23 | 2012-08-16 | Deciphera Pharmaceuticals, Llc | Enzyme modulators and treatments |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
WO2008051757A1 (en) | 2006-10-20 | 2008-05-02 | Irm Llc | Compositions and methods for modulating c-kit and pdgfr receptors |
-
2007
- 2007-09-12 US US11/854,293 patent/US7897762B2/en not_active Expired - Fee Related
- 2007-09-13 JP JP2009528474A patent/JP2010503701A/ja active Pending
- 2007-09-13 WO PCT/US2007/078394 patent/WO2008033999A2/en active Application Filing
- 2007-09-13 EA EA200970279A patent/EA200970279A1/ru unknown
- 2007-09-13 AU AU2007296441A patent/AU2007296441A1/en not_active Abandoned
- 2007-09-13 KR KR1020117013534A patent/KR20110074633A/ko not_active Application Discontinuation
- 2007-09-13 MX MX2009002813A patent/MX2009002813A/es not_active Application Discontinuation
- 2007-09-13 BR BRPI0716844-6A2A patent/BRPI0716844A2/pt not_active IP Right Cessation
- 2007-09-13 EP EP07842425A patent/EP2063896A4/en not_active Withdrawn
- 2007-09-13 KR KR1020097007593A patent/KR20090067175A/ko active IP Right Grant
- 2007-09-13 CA CA002664009A patent/CA2664009A1/en not_active Abandoned
-
2011
- 2011-01-26 US US13/014,020 patent/US20110118271A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2010503701A (ja) | 2010-02-04 |
AU2007296441A1 (en) | 2008-03-20 |
BRPI0716844A2 (pt) | 2013-10-22 |
US20090099190A1 (en) | 2009-04-16 |
EP2063896A2 (en) | 2009-06-03 |
MX2009002813A (es) | 2009-07-24 |
WO2008033999A2 (en) | 2008-03-20 |
KR20110074633A (ko) | 2011-06-30 |
CA2664009A1 (en) | 2008-03-20 |
WO2008033999A8 (en) | 2009-11-05 |
WO2008033999A3 (en) | 2008-08-07 |
US20110118271A1 (en) | 2011-05-19 |
US7897762B2 (en) | 2011-03-01 |
KR20090067175A (ko) | 2009-06-24 |
EP2063896A4 (en) | 2010-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200970279A1 (ru) | Ингибиторы киназ, полезные для лечения пролиферативных заболеваний | |
EA200970280A1 (ru) | Ингибиторы киназ, полезные для лечения пролиферативных заболеваний | |
EA201990001A1 (ru) | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 | |
PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
MX2018003351A (es) | Derivados de pirazolopirimidina como inhibidores de la btk para el tratramiento de cancer. | |
UA104849C2 (ru) | 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины как ингибиторы киназ janus | |
UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
PH12014501355B1 (en) | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors | |
EA201691294A2 (ru) | ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
EA201390550A1 (ru) | Способы ингибирования пролиферации клеток в egfr-стимулируемых злокачественных опухолях | |
EA201791946A1 (ru) | Лечение хронической реакции "трансплантат против хозяина" с применением ингибиторов syk | |
SI1631295T1 (sl) | Uporaba kondenziranih heterocikličnih spojin kotSCCE inhibitorjev za zdravljenje kožnih bolezni | |
EP2170337A4 (en) | NEW TRIAZOLOPYRIDAZINE | |
NO20070506L (no) | Fremgangsmater og mellomprodukter nyttige for fremstilling av kondenserte heterocykliske kinase inhibitorer. | |
WO2012034116A3 (en) | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders | |
WO2007149427A3 (en) | Tyrosine kinase inhibitors | |
MX2008012852A (es) | Quinazolinas para la inhibicion de pdk1. | |
MX2009003650A (es) | Nuevos imidazotiazoles e imidazoxazoles. | |
MX2021015826A (es) | Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
ATE499102T1 (de) | Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen | |
WO2007053573A3 (en) | Treatment of cancer with sorafenib | |
IL178675A0 (en) | Monocyclic heterocycles as kinase inhibitors | |
ATE502025T1 (de) | Arylcarboxamide und ihre verwendung als antitumormittel | |
AU2015314007B2 (en) | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | |
WO2008063760A3 (en) | Methods for treating cancer targeting transglutaminase |